Financial Data and Key Metrics Changes - The company reported adjusted EPS of $1.84 on $10.8 billion of premium revenue, which was below expectations [7][19] - The consolidated MCR for the quarter was 92.6%, reflecting a challenging medical cost environment [7][19] - Year-to-date, the consolidated MCR stands at 90.8% with an adjusted pre-tax margin of 2.7% [7] Business Line Data and Key Metrics Changes - In Medicaid, which represents 75% of total premium revenue, the MCR was reported at 92% with an adjusted pre-tax margin of 2.6% [8][19] - The Medicare segment reported a third quarter MCR of 93.6%, with higher utilization in high-acuity populations [8][20] - The Marketplace segment had a significantly higher-than-expected MCR of 95.6%, driven by elevated utilization [8][21] Market Data and Key Metrics Changes - The company anticipates full-year premium revenue to increase to approximately $42.5 billion [9][24] - The adjusted EPS guidance for 2025 has been revised down to approximately $14 per share, reflecting a consolidated MCR of 91.3% [9][24] - The medical cost trend for Medicaid is now expected to be 7%, which is 100 basis points higher than previous guidance [10][25] Company Strategy and Development Direction - The company aims to surpass the $50 billion premium revenue mark in the coming years, with a focus on winning RFPs and pursuing M&A opportunities [16] - The strategy includes reducing exposure in the Marketplace while stabilizing the risk pool [17] - The company is optimistic about Medicaid rates keeping pace with medical cost trends, with expectations for slight improvements [42][44] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging medical cost environment but expressed confidence in the long-term growth potential of the business [17][18] - The company views the current operating environment as temporary and expects rates to eventually align with medical cost trends [17][60] - Management highlighted the importance of state responsiveness to rate adjustments in light of increased medical costs [42][44] Other Important Information - The company has a strong capital foundation, with RBC ratios at 340% and total subsidiary capital 70% above state minimums [22] - Share repurchases totaled approximately 2.8 million shares at a cost of $500 million, reflecting confidence in the company's long-term value [23] - The company has an active pipeline of $54 billion in new opportunities over the next few years [16] Q&A Session Summary Question: Can you elaborate on the drivers of ACA MCR pressure in the quarter? - Management indicated that the pressure was due to increased medical cost trends across all categories, with a higher percentage of special enrollment membership contributing to the trend [34][35] Question: Are you expecting Medicaid rates to be in excess of the 7% cost trend? - Management expressed optimism that rates will at least keep pace with the trend, citing state responsiveness and a solid baseline for rate projections [41][42] Question: How does the expiration of subsidies affect your pricing assumptions? - Management stated that pricing was conservatively set to account for the expiration of subsidies, with an aim to break even or better in the Marketplace segment [46][47] Question: What is the outlook for embedded earnings? - Management indicated that embedded earnings are expected to be realized over time, with some components contributing positively in the upcoming year [62][65] Question: Can you discuss the M&A pipeline and capital allocation priorities? - Management confirmed that capital priorities remain focused on organic growth, inorganic growth, and returning capital to shareholders, with a full pipeline of actionable M&A opportunities [71][74]

Financial Data and Key Metrics Changes - The company reported adjusted earnings per share of $1.84 on premium revenue of $10.8 billion, which was below expectations [5][20] - The consolidated Medical Care Ratio (MCR) was 92.6%, reflecting a challenging medical cost environment [5][20] - Year-to-date, the consolidated MCR stands at 90.8% with an adjusted pretax margin of 2.7% [5][20] - The full-year 2025 adjusted earnings per share guidance has been revised down to approximately $14, which is $5 below prior guidance of $19 per share [7][27] Business Line Data and Key Metrics Changes - In Medicaid, which represents 75% of total premium revenue, the MCR was reported at 92% with an adjusted pretax margin of 2.6% [5][21] - The Medicare segment reported a third-quarter MCR of 93.6%, with higher utilization in high-acuity populations [6][21] - The marketplace segment had a significantly higher MCR of 95.6%, indicating elevated utilization compared to risk adjustment revenue [7][21] Market Data and Key Metrics Changes - The company anticipates premium revenue growth in its current footprint and new Medicaid contracts in Georgia and Texas, targeting $46 billion in revenue for 2026 [12][31] - The marketplace business is expected to face revenue headwinds due to pricing strategies aimed at reducing exposure [13][31] Company Strategy and Development Direction - The company aims to surpass $50 billion in premium revenue in the coming years, with a strong pipeline of $54 billion in new opportunities [17][91] - The acquisition pipeline is robust, focusing on smaller health plans that may consider strategic options due to current operating challenges [18][91] - The company is strategically reducing its footprint in the marketplace to stabilize risk pools and improve margins [32][91] Management's Comments on Operating Environment and Future Outlook - Management noted that the medical cost trend is higher than expected, driven by increased utilization across various categories [6][21] - The company remains optimistic about Medicaid rates keeping pace with cost trends, citing responsiveness from state partners [49][51] - The outlook for 2026 suggests a potential return to target margins as rates are expected to improve [60][62] Other Important Information - The effective tax rate in the third quarter dropped significantly due to federal tax credits and lower non-deductible expenses [22] - The company repurchased approximately 2.8 million shares at a cost of $500 million, indicating confidence in the value of its shares [25][91] Q&A Session Summary Question: Can you elaborate on the drivers of ACA MLR pressure in the quarter? - The pressure was strictly related to increased medical cost trends across all categories, with a higher percentage of special enrollment membership contributing to the trend [40][41] Question: Are you expecting Medicaid rates to be in excess of the 7% cost trend? - Management expressed optimism that rates will at least keep pace with the trend, citing responsive state actions and visibility into cost categories [48][49] Question: How does the expiration of subsidies affect your pricing assumptions? - The company has priced for the expiration of subsidies, targeting breakeven or better margins, with significant price increases planned [54][56] Question: What is the outlook for embedded earnings? - The company has $8.65 in embedded earnings, with expectations for a portion to emerge in 2026, although the timing may be affected by current margin levels [77][80] Question: Can you break down the performance of the Medicare business? - The Medicare business is undergoing rejuvenation, with expectations for slight margin erosion in MMPs transitioning to Phydes and Hydes, but overall starting at margin neutral for next year [82][87] Question: How is the M&A pipeline developing? - The M&A pipeline is full of actionable opportunities, with a focus on acquiring revenue streams from struggling local health plans at or near book value [89][91]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Ventyx Biosciences, Inc. (VTYX) increased by 108% to $8.05 - Brera Holdings PLC (SLMT) rose by 49% to $12.50 - Safe & Green Holdings Corp. (SGBX) gained 39% to $3.18 - American Rebel Holdings, Inc. (AREB) up by 26% to $2.71 - Tango Therapeutics, Inc. (TNGX) increased by 18% to $10.25 - Garrett Motion Inc. (GTX) rose by 14% to $14.30 - ETHZilla Corporation (ETHZ) gained 12% to $17.61 - D-Wave Quantum Inc. (QBTS) increased by 11% to $30.40 - IonQ, Inc. (IONQ) rose by 10% to $61.04 - Megan Holdings Limited (MGN) up by 7% to $2.31 [3] Premarket Losers - Splash Beverage Group, Inc. (SBEV) decreased by 21% to $2.06 - Molina Healthcare, Inc. (MOH) down by 18% to $158.44 - SCHMID Group N.V. (SHMD) fell by 18% to $3.18 - Beyond Meat, Inc. (BYND) decreased by 18% to $2.91 - Agencia Comercial Spirits Ltd (AGCC) down by 16% to $5.07 - Super League Enterprise, Inc. (SLE) fell by 13% to $2.25 - Armata Pharmaceuticals, Inc. (ARMP) decreased by 12% to $5.99 - Applied DNA Sciences, Inc. (BNBX) down by 12% to $4.19 - Ribbon Communications Inc. (RBBN) fell by 12% to $3.49 - Tamboran Resources Corporation (TBN) decreased by 11% to $21.81 [4]

Molina Healthcare shares fell about 20% in premarket trading on Thursday, a day after the insurer cut its annual profit forecast for the third time this year, driven by higher medical costs across its... ...

Core Insights - Molina Healthcare Inc. shares experienced a significant decline of 19.34% to $157.39 in after-hours trading following the release of its third-quarter earnings [1] Financial Performance - The company reported third-quarter GAAP earnings of $1.51 per diluted share, a decrease from $5.65 in the same quarter last year [2] - Adjusted earnings were $1.84 per share, down from $6.01 year-over-year [2] - Premium revenue increased by 12% year-over-year, reaching $10.8 billion [2] Medical Care Ratios - The consolidated medical care ratio (MCR) for Q3 rose to 92.6%, up from 89.2% a year earlier [3] - Medicaid MCR was reported at 92.0%, Medicare at 93.6%, and Marketplace at 95.6% [3] Earnings Contribution - Medicaid contributed $3.52 per diluted share to adjusted earnings, while losses from Medicare and Marketplace amounted to $1.68 per share [4] Full-Year Guidance - The company revised its premium revenue forecast to approximately $42.5 billion and expects full-year 2025 adjusted earnings of around $14 per diluted share [5] - The outlook change is attributed to rising medical costs across all segments, with the Marketplace business facing "unprecedented" cost trends [5] Preliminary Outlook for 2026 - The preliminary outlook for adjusted earnings per share in 2026 is expected to be similar to the full-year 2025 guidance, with reduced exposure to the Marketplace [6] Stock Performance - Molina Healthcare's stock has declined 32.96% year-to-date in 2025, trading within a range of $151.95 to $359.97 [7] - The company has a market capitalization of $10.58 billion, an average daily volume of 1.04 million shares, and a price-to-earnings ratio of 9.62 [7]

The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose: (1) material, adverse facts concerning Molina's "medical cost trend assumptions"; (2) that Molina was experiencing a "dislocation between premium rates and medical cost trend"; (3) that Molina's near term growth was dependent on a lack of "utilization of behavioral health, pharmacy, and inpatient and outpatient services"; (4) as a result, Molina's financial guidance for fisc ...

Core Insights - Molina (MOH) reported $11.48 billion in revenue for Q3 2025, marking an 11% year-over-year increase, but EPS fell to $1.84 from $6.01 a year ago, indicating a significant decline in profitability [1] - The revenue exceeded the Zacks Consensus Estimate of $10.9 billion by 5.28%, while the EPS fell short of the consensus estimate of $3.97 by 53.65% [1] Financial Performance Metrics - Molina's total Membership Care Ratio (MCR) was 92.6%, surpassing the average estimate of 90.3% [4] - The MCR for Medicare was reported at 93.6%, exceeding the estimated 87% [4] - The MCR for Marketplace was 95.6%, compared to the estimated 84.7% [4] Membership and Revenue Breakdown - Total ending membership was 5.63 million, slightly below the average estimate of 5.74 million [4] - Medicaid membership stood at 4.64 million, compared to the estimated 4.8 million [4] - Premium revenue reached $10.84 billion, exceeding the estimate of $10.31 billion, reflecting an 11.8% increase year-over-year [4] - Premium tax revenue was $506 million, slightly above the estimate of $474.87 million, but showed a year-over-year decline of 0.4% [4] - Medicare premium revenue was $1.61 billion, surpassing the estimate of $1.48 billion, with a year-over-year increase of 17.8% [4] - Medicaid premium revenue was $8.02 billion, exceeding the estimate of $7.66 billion, reflecting a 4.5% year-over-year increase [4] - Marketplace premium revenue was $1.2 billion, significantly above the estimate of $1.1 billion, showing an impressive 81.6% increase year-over-year [4] - Investment income was reported at $108 million, exceeding the estimate of $99.93 million, but reflecting an 8.5% year-over-year decline [4] - Other revenue was $22 million, slightly above the estimate of $21.47 million, with a year-over-year increase of 10% [4] Stock Performance - Molina's shares have returned +7.8% over the past month, outperforming the Zacks S&P 500 composite's +1.1% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Molina's quarterly earnings were reported at $1.84 per share, significantly missing the Zacks Consensus Estimate of $3.97 per share, representing an earnings surprise of -53.65% [1] - The company posted revenues of $11.48 billion for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 5.28% and showing an increase from $10.34 billion year-over-year [2] - Molina's stock has underperformed, losing approximately 32.4% since the beginning of the year, while the S&P 500 has gained 14.5% [3] Earnings Performance - Over the last four quarters, Molina has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is $3.38, with expected revenues of $11.07 billion, and for the current fiscal year, the EPS estimate is $18.87 on revenues of $44.54 billion [7] Market Outlook - The company's earnings outlook is crucial for investors, as it reflects current consensus expectations and any recent changes [4] - The trend of estimate revisions for Molina was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The Medical - HMOs industry, to which Molina belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable industry outlook [8] Competitor Insights - Cigna, another company in the same industry, is expected to report quarterly earnings of $7.70 per share, reflecting a year-over-year increase of 2.5%, with revenues projected at $67.19 billion, up 5.5% from the previous year [9]

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Molina (MOH) To Contact Him Directly To Discuss Their Options If you purchased or acquired Molina securities between February 5, 2025 and July 23, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar E ...

Molina Healthcare on Wednesday cut its annual profit forecast anticipating higher medical care costs to weigh on its results for the rest of the year. ...